Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02670577 · ClinicalTrials.gov registry record
Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry
A clinical trial, sponsored by Agendia.
- Completed
- Registry status
- 481
- Enrollment target
NCT02670577: Completed study, sponsored by Agendia.
NCT02670577 is a clinical trial that has completed, run by Agendia. The registered enrollment target is 481 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02670577 has completed, sponsored by Agendia.
- COMPLETED
- Registry status
- 481 participants
- Enrollment target
Study Summary
The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients. In addition, the impact of MammaPrint on treatment in patients with T1a/T1b and pN0/pN1 (up to 1 node), Triple Negative or HER2-positive tumors will be assessed.
Primary Outcome
Compare treatment decision before and after test results.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 481 participants |
| Start Date | 2015-11 |
| Est. Completion | 2017-08 |
What the finished NCT02670577 record still lists
NCT02670577 is an observational study that tracks outcomes without assigning an intervention. The registered 481 participants enrollment target is mid-sized for trials with a published cap.
The record links to 0 conditions, and to 0 interventions.
NCT02670577 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02670577 about?
NCT02670577 is a clinical study titled "Measuring the Impact of MammaPrint on Adjuvant and Neoadjuvant Treatment in Breast Cancer Patients: A Prospective Registry". The scope of this study is to measure the impact of MammaPrint on treatment in Hormone Receptor (HR)-positive HER2-negative breast cancer patients. In addition, the impact of MammaPrint on treatment in patients with T1a/T1b and pN0/pN1 (up to 1 node), Triple Negative or HER2-positive tumors will be...
What is the current status of trial NCT02670577?
This trial is currently completed. The enrollment target is 481 participants. The study started on 2015-11. Estimated completion is 2017-08.
Who is sponsoring clinical trial NCT02670577?
This trial is sponsored by Agendia, which has 6 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04449458 · 482 participants · NA
The Positively Quit Trial for Smoking Cessation
- NCT07079631 · 482 participants · Phase 1
A Clinical Study to Test if an Investigational Treatment Called BNT314 When Used in Combination With Another Investigational Treatment BNT327 and Chemotherapy, is Beneficial and Safe for Patients With Advanced Colorectal Cancer
- NCT01954992 · 480 participants · Phase 3
Glufosfamide Versus 5-FU in Second Line Metastatic Pancreatic Cancer
- NCT03023696 · 480 participants · NA
Can Prophylactic Foraminotomy Prevent C5 Palsy
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia